ViewRay, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRAYQ research report →
Companywww.viewray.com
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns.
- CEO
- Paul Ziegler Jr.
- IPO
- 2015
- Employees
- 295
- HQ
- Denver, CO, US
Price Chart
Valuation
- Market Cap
- $18.34K
- P/E
- -0.04
- P/S
- 0.04
- P/B
- 0.05
- EV/EBITDA
- 0.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 9.83%
- Op Margin
- -104.81%
- Net Margin
- -105.21%
- ROE
- -85.33%
- ROIC
- -60.29%
Growth & Income
- Revenue
- $102.21M · 45.76%
- Net Income
- $-107,330,000 · 2.47%
- EPS
- $-0.59 · 11.94%
- Op Income
- $-107,127,000
- FCF YoY
- -50.21%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.34
- Avg Volume
- 69.64K
Get TickerSpark's AI analysis on VRAYQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VRAYQ Coverage
We haven't published any research on VRAYQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VRAYQ Report →